Taysha Gene Therapies Announces Presentation on New Preclinical Data for TSHA-102 in Rett Syndrome at Upcoming American Society of Gene and Cell Therapy 26th Annual Meeting
April 27 2023 - 4:52PM
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene
therapy company focused on developing and commercializing AAV-based
gene therapies for the treatment of monogenic diseases of the
central nervous system (CNS), today announced that an abstract
related to its TSHA-102 program in Rett syndrome was accepted for
presentation at the upcoming American Society of Gene and Cell
Therapy (ASGCT) 26th Annual Meeting, taking place in Los Angeles,
CA from May 16-20, 2023. The abstract includes new preclinical data
from a Taysha-sponsored study for TSHA-102, a self-complementary
intrathecally delivered AAV9 gene transfer therapy in clinical
evaluation for Rett syndrome, a rare neurodevelopmental disorder
caused by mutations in the X-linked MECP2 gene.
Details for the presentation are as follows:
Abstract Title: A Human-Ready Regulated
AAV9/miniMECP2-miRARE Gene Therapy (TSHA-102) Improves Survival,
Weight, and Behavior After Intracerebroventricular (ICV) Dosing in
the Neonatal Knockout Rett (RTT) Mouse Model
Presenter: Sarah Sinnett, Ph.D., University of
Texas Southwestern Medical Center, Co-Inventor of miRARE
technologyPoster Session Date/Time: Friday, May 19
at 12-2 PM PTPoster Session: Friday Poster
SessionPoster Number: 1365
Additional details can be found at the ASGCT 26th Annual
Meeting website.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program. Together, we leverage our fully integrated platform—an
engine for potential new cures—with a goal of dramatically
improving patients’ lives. More information is available at
www.tayshagtx.com.
Company Contact:Hayleigh Collins Director, Head
of Corporate CommunicationsTaysha Gene
Therapieshcollins@tayshagtx.com
Media Contact:Carolyn HawleyCanale
Communicationscarolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Jul 2023 to Jul 2024